Anti-Human VE-Cadherin – CF®633

Anti-Human VE-Cadherin – CF®633

Product No.: V134CF

[product_table name="All Top" skus="V134"]

- -
- -
Target
VE-Cadherin
Product Type
Polyclonal Antibody
Alternate Names
Vascular Endothelial Cadherin, Cadherin-5 (CDH5), 7B4, CD144, VE-Cad, VEC

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Goat
Immunogen
NS0-Derived Recombinant Human VE-Cadherin Extracellular Domain
Product Concentration
0.2 mg/ml
Formulation
This CF®633 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This CF®633 conjugate is stable when stored at 2-8°C, protected from light. Do not freeze.
Country of Origin
USA
Shipping
2-8°C
Excitation Laser
633 nm or 635 nm
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Emission Max
630/650 nm

Description

Description

Specificity
Goat Anti-Human Vascular Endothelial Cadherin (VE-Cadherin) recognizes Human VE-Cadherin. This antigen affinity purified polyclonal antibody was purified using a proprietary chromatographic technique that includes covalently immobilizing the antigen proteins or peptides to agarose based beads. This purification method enhances specificity, reduces nonspecific binding of extraneous IgG and provides you with the most reliable reagent available for your early discovery research.
Background
Vascular endothelial-cadherin (VE-Cadherin) also known as cadherin-5 is an endothelial specific, homophilic adhesion molecule located at the lateral cell surface.1 VE-Cadherin is crucial for the proper assembly of vascular structures and the maintenance of vascular integrity.2 It plays a pivotal role in the formation, maturation and remodeling of the vascular wall.3 VE-cadherin is a positive and endothelial cell-specific regulator of transforming growth factor-beta (TGF-beta) signaling. Therefore, the reduction or inactivation of VE-cadherin may contribute to progression of diseases where TGF-beta signaling is impaired.4
NCBI Gene Bank ID

References & Citations

1. Vestweber, D. et al. (1997) J Cell Sci. 110: 583
2. Lambert, O. et al. (2008) Biochem Soc Trans. 36: 189
3. Gavard, J. et al. (2009) FEBS Lett. 583: 1
4. Dejana, E. et al. (2008) EMBO J. 27: 993
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.